Removal of substances from the Revised In Commerce List

In 2001, Health Canada initiated a process to identify substances used in the Food and Drugs Act (F&DA) products on the market between January 1,1987 and September 13,2001 and place them on an administrative list now known as the Revised In Commerce List (R-ICL). Prioritization of the Revised In Commerce List (R-ICL) was completed in 2016. Based on available information, Health Canada has identified 669 substances as discontinued, never marketed in Canada, or in Canadian commerce below the New Substances Notification Regulation (NSNR) (Chemicals and Polymers) lowest trigger for regulatory reporting.

The available information considered included Health Canada records and the results of a mandatory survey pursuant to section 71 of CEPA 1999 published in the Canada Gazette, Part I, in January 2017. An objective of the survey was the collection of data on the commercial status of certain substances listed on the R-ICL. As the 669 substances have limited or no current commercial presence in Canada based on the available information, they are expected to be less likely to cause harm to human health or the environment as a result of their limited anticipated exposure potential. As such, Health Canada proposes to remove these 669 substances from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other initiatives under the Canadian Environmental Protection Act, 1999 (CEPA 1999). These substances, if removed from the R-ICL, could be notifiable under the NSNR of CEPA 1999.

In September 2020, a consultation document was released regarding the proposed delisting of these 669 substances from the R-ICL, and a related notice was published in the Canada Gazette, Part I: Vol. 154, No 39 – September 26, 2020. This notice is entitled Notice of Intent to Remove Low Volume or Discontinued Substances from the Revised In Commerce List. Publication of this notice initiated a 60-day comment period. Following the 60-day comment period, Health Canada will finalize its delisting decision with respect to each of the 669 substances and publish a subsequent notice in the Canada Gazette, Part I.

Contact information

Environmental Assessment Unit 1
Health Canada
Mail stop PL 4905B
Ottawa, ON K1A 0K9
Telephone: 1-866-996-9913 (in Canada) or 613-948-3591
Fax: 613-952-5354
Email: hc.eau-uee.sc@canada.ca

Please include your full contact information: name, address, phone number and email address.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: